"The Safety Profile of Teriflunomide for Multiple Sclerosis Treatment" - Amy Jacob
It’s important, says Aaron Miller, MD, medical director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis, to look at the safety profile of the drug. These safety data in the TOPIC extension trial were very comparable to those that were seen in the pivotal phase 3 relapsing remitting trials. “These are generally very mild, and principally occur early in the course of treatment,” he said in a video interview.
- Aaron Miller, MD, Professor, Neurology, Icahn School of Medicine at Mount Sinai, Medical Director, Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Additional Coverage:
MD Magazine
Two Mount Sinai Experts Receive Honors From the National Multiple Sclerosis Society
Sep 16, 2021 View All Press Releases